Healthcare
ByDid the Zealand Pharma–Roche Obesity Partnership Hit an Early Roadblock?
A closely watched obesity drug collaboration between Zealand Pharma and Roche has encountered an unexpected setback after early…
Indian Biopharma Faces Freight Surge Amid US-Iran Escalation
India’s biopharma sector confronts $300-500M export losses as US-Iran war disrupts Gulf shipping, spiking container surcharges to $3,500–$5,000…
What broader implications does Zealand Pharma’s petrelintide trial setback raise for the GLP-1 obesity market?
Trial Context Recap ZUPREME-1 delivered 10.7% peak weight loss over 42 weeks across 493 patients, surpassing placebo but…
The $10B+ Pharma Titans of 2025: Fortress Builders or House of Cards?
In 2025, only nine pharmaceutical brands crossed the $10 billion revenue threshold, collectively generating $125B+ while representing 25% of global pharma sales—yet their…
Can J&J’s Newly FDA-Approved Dual-Energy Ablation Catheter Help It Reclaim Ground Lost to Boston Scientific and Medtronic in PFA?
Key Highlights A Strategic Answer to Lost PFA Ground Johnson & Johnson enters the U.S. dual-energy ablation market…
J&J’s $1 Billion Firefly Bio Buy: Has Big Pharma Finally Found a Way to Drug the ‘Undruggable’ KRAS?
Key Highlights A Novel Modality for a Notoriously Hard Target At the center of the acquisition is Firefly…
